Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.47 |
| ▸ | MAOA | P21397 | 6/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4323109 | 0.87 | MAOB (0.48) | MAOBMAOANPC1ALDH1A1HPGD | |
| SCHEMBL2688515 | 0.86 | MAOB (0.53) | MAOBMAOANPC1ALDH1A1HPGD | |
| SCHEMBL1962780 | 0.84 | MAOB (0.51) | MAOBMAOANPC1ALDH1A1HPGD | |
| SCHEMBL1961908 | 0.83 | MAOB (0.54) | MAOBMAOANPC1ALDH1A1HPGD | |
| SCHEMBL4549091 | 0.78 | MAOB (0.43) | MAOBMAOANPC1ALDH1A1HPGD | |
| SCHEMBL949460 | 0.73 | MAOB (0.51) | MAOBMAOANPC1ALDH1A1HPGD | |
| SCHEMBL2380553 | 0.72 | MAOB (0.59) | MAOBMAOAALOX5 | |
| SCHEMBL3921148 | 0.72 | ALOX5AP (0.43) | MAOBMAOARAB9ASMN1; SMN2ALOX5 | |
| SCHEMBL4549093 | 0.72 | PREP (0.35) | MAOBNPC1ALDH1A1NFKB1RAB9A | |
| SCHEMBL1964162 | 0.72 | MAPT (0.54) | MAOBMAOANPC1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009111428-A2 | METHODS FOR SYNTHESIZING GLYCINOLS, GLYCEOLLINS I AND II, COMPOSITIONS OF SELECTED INTERMEDIATES, AND THERAPEUTIC USES THEREOF | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2009-09-11 | — | — | WO | claimed |
| US-8563599-B2 | Methods for synthesizing glycinols, glyceollins I and II, compositions of selected intermediates, and therapeutic uses thereof | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 2013-10-22 | — | — | US | disclosed |
| US-8507549-B2 | Methods for synthesizing glycinols, glyceollins I and II and isoflavenes and chromanes using a Wittig reaction, and compositions made therewith | THE UNIVERSITY OF TOLEDO (US) | 2013-08-13 | — | — | US | disclosed |
| US-20120115942-A1 | Methods for Synthesizing Glycinols, Glyceollins I and II and Isoflavenes and Chromanes Using A Wittig Reaction, and Compositions Made Therewith | THE UNIVERSITY OF TOLEDO | 2012-05-10 | — | — | US | disclosed |
| US-20110144195-A1 | METHODS FOR SYNTHESIZING GLYCINOLS, GLYCEOLLINS I AND II, COMPOSITIONS OF SELECTED INTERMEDIATES, AND THERAPEUTIC USES THEREOF | XAVIER UNIVERSITY OF LOUISIANA | 2011-06-16 | — | — | US | disclosed |
| WO-2009111428-A2 | METHODS FOR SYNTHESIZING GLYCINOLS, GLYCEOLLINS I AND II, COMPOSITIONS OF SELECTED INTERMEDIATES, AND THERAPEUTIC USES THEREOF | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144195-A1 | METHODS FOR SYNTHESIZING GLYCINOLS, GLYCEOLLINS I AND II, COMPOSITIONS OF SELECTED INTERMEDIATES, AND THERAPEUTIC USES THEREOF | GPER1, ESR2, GNE | MAOB 3183/4885MAOA 4124/4885NPC1 2064/4885 |
| US-20120115942-A1 | Methods for Synthesizing Glycinols, Glyceollins I and II and Isoflavenes and Chromanes Using A Wittig Reaction, and Compositions Made Therewith | UGGT1, GCG, UGT8 | MAOB 669/4885MAOA 842/4885NPC1 2595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.